Acquired polycythemia vera
Therapeutic area
Rheumatology
Rare disease
Yes
- Definition
- Polycythemia vera (PV) is an acquired myeloproliferative disorder characterized by an elevated absolute red blood cell mass caused by uncontrolled red blood cell production, frequently associated with uncontrolled white blood cell and platelet production.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Acquired polycythemia vera
- Therapeutic area
- Rheumatology
- acquired polycythemia vera
- Osler-Vaquez disease
- PV
- Vaquez disease
- acquired primary erythrocytosis
- polycythaemia rubra vera
- polycythemia rubra vera
- polycythemia vera
- polycythemia vera, somatic
- PRV
- primary polycythemia
- Severity
- Severe
- Genetic
- Hereditary
- Hematology
- Immunology
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0009891
- Parent condition
- MONDO:0001115
Related records
Broader conditions (33)
- Bone cancer
- Bone disorder
- Bone marrow cancer
- Bone marrow disorder
- Bone marrow neoplasm
- Bone neoplasm
- Cancer
- Cancer or benign tumor
- Connective tissue disorder
- Connective tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Erythroid neoplasm
- Familial polycythemia
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Hereditary disease
Trials (272)
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
- 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV
- A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)
- A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
- A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- A Phase 1 Study of XL019 in Adults With Polycythemia Vera
- A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
- A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
- A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
- A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
- A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
- A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera
- A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- A Safety Study of XL019 in Adults With Myelofibrosis
- A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
Approved drugs (4)
- Momelotinib dihydrochloride
- Pacritinib citrate
- Ropeginterferon alfa-2B
- Ruxolitinib phosphate
Drugs in development (43)
- Acetylcysteine Phase 1
- Anagrelide Phase 3
- Arsenic trioxide Phase 1
- Ascorbic acid Phase 1
- Aspirin Phase 3
- Bomedemstat Phase 2
- Clopidogrel Phase 2
- Cytarabine Phase 1
- Dasatinib anhydrous Phase 2
- Daunorubicin Phase 1
- Durvalumab Phase 1
- Erlotinib Phase 2
- Fludarabine phosphate Phase 2
- Givinostat Phase 1
- Givinostat hydrochloride Phase 3
- Hydroxyurea Phase 3
- Idasanutlin Phase 2
- Imatinib mesylate Phase 2
- Imetelstat Phase 2
- Interferon alfa Phase 3
Other linked drugs (1)
- Fedratinib